This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Sat May 25, 2013 5:40 am


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 2 posts ] 
Author Message
PostPosted: Wed Nov 14, 2012 3:27 am 
Offline
Family Elder
User avatar

Joined: Wed Oct 14, 2009 3:00 pm
Posts: 1689
Image

Nuron Biotech Inc. said Tuesday it has completed enrollment of 500 patients for a pivotal phase-III study evaluating the safety and effectiveness of the company’s experimental multiple sclerosis treatment.

Phase-III studies are typically the last hurdle a drug developer must clear before seeking approval for a new drug candidate.

Nuron, an Exton, Pa., specialty biologics and vaccines company, is developing NU100 to treat relapsing remitting multiple sclerosis.

Shankar Musunuri, the company’s founder and CEO, said it expects to complete the study in late 2013.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2872

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis


Top
 Profile  
 
PostPosted: Wed Nov 14, 2012 4:48 am 
Offline
Volunteer Moderator
User avatar

Joined: Sat Nov 20, 2004 4:00 pm
Posts: 2717
Quote:
About NU100
NU100 is a proprietary recombinant human interferon beta-1b produced utilizing proprietary refolding process technology. It is being developed as a standalone molecule for the treatment of relapsing remitting multiple sclerosis (RRMS) and as a new molecular entity based on positive opinion from the European Medicines Agency and the Food and Drug Administration.

Patients treated with currently marketed interferon beta-1b products have up to 40 percent neutralizing antibody prevalence after two years of treatment. NU100 is essentially aggregate-free compared to those products; therefore, it should result in lower immune responses, potentially improving overall long-term clinical efficacy and improving the tolerability and safety for RRMS patients presently requiring therapy with interferon beta-1b.


I think the problem with interferon beta-1b's high rate of antigenicity is the fact that it's produced in bacteria and is therefore not glycosylated (doesn't have any attached sugar groups). In contrast, human interferon beta is glycosylated and is identical to interferon beta-1a. The lack of glycosylation on an otherwise normally glycosylated protein will make the 1b form appear as a foreign protein and increase its antigenicity and its tendency to elicit neutralizing antibodies.

NHE


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. Interferon Beta DNA treatment

scoobyjude

4

1445

Mon Apr 02, 2007 5:37 pm

scoobyjude View the latest post

There are no new unread posts for this topic. Estrogen based treatment

NHE

2

1220

Wed Sep 05, 2007 5:18 pm

NHE View the latest post

There are no new unread posts for this topic. oral treatment podcast

dignan

0

1695

Sun Jan 25, 2009 10:27 am

dignan View the latest post

There are no new unread posts for this topic. Monthly Treatment vs Orals

RickB

1

909

Thu Apr 19, 2012 8:14 pm

MarkLavelle View the latest post

There are no new unread posts for this topic. Another drug treatment at early stage

bromley

1

1413

Wed Oct 26, 2005 11:35 am

Brownsfan View the latest post

 


Who is online

Users browsing this forum: No registered users


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: